Related references
Note: Only part of the references are listed.Antibodies to watch in 2022
Helene Kaplon et al.
MABS (2022)
EBV associated T- and NK-cell lymphoproliferative diseases: A comprehensive overview of clinical manifestations and novel therapeutic insights
Arman Shafiee et al.
REVIEWS IN MEDICAL VIROLOGY (2022)
Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report
Juan Wang et al.
WORLD JOURNAL OF CLINICAL CASES (2022)
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei (Murphy) Sun et al.
DIAGNOSTICS (2022)
The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma
Hyunsung Kim et al.
LIFE-BASEL (2022)
The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma
Linyan Xu et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2022)
A 10-year survival update on early-stage extranodal natural killer/T-cell lymphoma with 'sandwich' therapy
Chunli Yang et al.
ACTA ONCOLOGICA (2022)
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
Ajay Major et al.
HAEMATOLOGICA (2022)
First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China
Yue Chai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4
Jia Huo et al.
INVESTIGATIONAL NEW DRUGS (2022)
Comprehensive analysis of the differential cellular and EBV miRNA expression profiles in mature T and NK cell lymphomas
Zheng Cao et al.
PATHOLOGY RESEARCH AND PRACTICE (2022)
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
John C. Reneau et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Genetic Landscape of Peripheral T-Cell Lymphoma
Vivian Hathuc et al.
LIFE-BASEL (2022)
GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).
Huiqiang Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma
Gehong Dong et al.
LEUKEMIA (2022)
DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study
Gao Yan et al.
BLOOD (2022)
KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas
Bimarzhan Assatova et al.
BLOOD (2022)
Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
Yuta Ito et al.
BLOOD (2022)
Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma
Bethany L. Mundy-Bosse et al.
BLOOD CANCER DISCOVERY (2022)
Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
Jason Yongsheng Chan et al.
LIFE-BASEL (2021)
Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial
H-Y Yhim et al.
ANNALS OF ONCOLOGY (2021)
The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma
Jin Hyun Kang et al.
BMC CANCER (2021)
(Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV plus ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study
Bradley M. Haverkos et al.
BLOOD (2021)
Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial
Lei Zhang et al.
BLOOD (2021)
Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen
Gao Yan et al.
BLOOD (2021)
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
Alison J. Moskowitz et al.
BLOOD (2021)
Association of B Symptoms With Plasma EBV-DNA Copy Number and Cytokine Profiles in Patients With Nasal Type Extranodal Natural Killer/T-Cell Lymphoma (ENKTL): A Mechanism and Prognostic Study
Y.T. Zhang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
Huiqiang Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide A case report
Jingyan Xu et al.
MEDICINE (2021)
A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma
Xiao-Peng Tian et al.
BLOOD (2021)
Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers
Boheng Li et al.
CANCERS (2021)
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells
Elina Parri et al.
BLOOD ADVANCES (2021)
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
Won Seog Kim et al.
ANNALS OF HEMATOLOGY (2021)
SINTILIMAB PLUS CHIDAMIDE FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A PROSPECTIVE, MULTICENTER, SINGLE‐ARM, PHASE IB/II TRIAL (SCENT)
H. Huang et al.
HEMATOLOGICAL ONCOLOGY (2021)
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas
Jie Ji et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
NK-/T-cell lymphomas
Hua Wang et al.
LEUKEMIA (2021)
Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate
Zhiyuan Zhou et al.
SCIENTIFIC REPORTS (2021)
Current Progress in Investigating Mature T- and NK-Cell Lymphoma Gene Aberrations by Next-Generation Sequencing (NGS)
Lifen Zhu et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
Nurulhuda Mustafa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
Rong Tao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
Jaap A. van Doesum et al.
HEMASPHERE (2021)
LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma
Liang Wang et al.
THERANOSTICS (2021)
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
Seok Jin Kim et al.
CANCER RESEARCH AND TREATMENT (2020)
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
Junhun Cho et al.
MODERN PATHOLOGY (2020)
Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis
Atif Saleem et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination
Maria Cosenza et al.
APOPTOSIS (2020)
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
Jie Xiong et al.
CANCER CELL (2020)
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
Christopher P. Fox et al.
LANCET HAEMATOLOGY (2020)
Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma
Changqian Bao et al.
TRANSLATIONAL CANCER RESEARCH (2020)
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
Seok Jin Kim et al.
BLOOD (2020)
Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma
Qiong Li et al.
BIOMARKER RESEARCH (2020)
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
Jing Quan Lim et al.
LEUKEMIA (2020)
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
Lijun Du et al.
ONCOTARGETS AND THERAPY (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen et al.
CANCERS (2020)
Increased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas
Yan Zhang et al.
FRONTIERS IN ONCOLOGY (2020)
Recent Update of HDAC Inhibitors in Lymphoma
I-Chung Chen et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
Sarah Reinke et al.
BLOOD (2020)
Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study
Qingqing Cai et al.
BLOOD (2020)
Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
Jun Cai et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives
Ningjing Lin et al.
CHINESE JOURNAL OF CANCER RESEARCH (2020)
Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications
Can Kucuk et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma
Sung Won Lim et al.
LEUKEMIA & LYMPHOMA (2019)
Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis
Jumei Liu et al.
HUMAN PATHOLOGY (2019)
c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma
Linan Zhu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Molecular pathogenic pathways in extranodal NK/T cell lymphoma
Sanjay de Mel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma
Qingqing Cai et al.
FRONTIERS IN ONCOLOGY (2019)
Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders
Li-Min Gao et al.
CANCER BIOLOGY & THERAPY (2019)
What we should know about natural killer/T-cell lymphomas
Jie Xiong et al.
HEMATOLOGICAL ONCOLOGY (2019)
High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments
Hani Nakhoul et al.
MSPHERE (2019)
Survivin is a prognostic marker and therapeutic target for extranodal, nasal-type natural killer/T cell lymphoma
Li Zhang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
Owen A. O'Connor et al.
BLOOD (2019)
DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
Chidimma Agatha Akpa et al.
PLOS ONE (2019)
MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1
Yu Chang et al.
CANCER BIOLOGY & THERAPY (2019)
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma
Toshihiro Nagato et al.
LABORATORY INVESTIGATION (2019)
Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy
Keisuke Kawamoto et al.
HEMATOLOGICAL ONCOLOGY (2018)
Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center
Jingwen Wang et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes
Jonathan E. Brammer et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression
Hui-Shan Huang et al.
HUMAN PATHOLOGY (2018)
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
Olli Dufva et al.
NATURE COMMUNICATIONS (2018)
Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival
Lisha Lu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Tammy Linlin Song et al.
BLOOD (2018)
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
Lauren P. McLaughlin et al.
BLOOD (2018)
Frequent Mutations in Natural Killer/T Cell Lymphoma
Yanjie Zhang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
A phase II trial of bevacizumab-GemAOD regimen for newly diagnosed extranodal NK/T cell lymphoma.
Zhiming Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)
Yan Ting Hee et al.
Oncotarget (2018)
Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Robert W. Chen et al.
BLOOD (2018)
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Ian W. Flinn et al.
BLOOD (2018)
Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia
Austin B. Henslee et al.
BIOMARKER RESEARCH (2018)
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Steven M. Horwitz et al.
BLOOD (2018)
PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing l-asparaginase: efficacy and safety
Thomas S. Y. Chan et al.
ANNALS OF HEMATOLOGY (2018)
Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type
Jae-Cheol Jo et al.
ANNALS OF HEMATOLOGY (2017)
The clinical significance of c-MYC expression, rearrangement, and copy number gain in extranodal NK/T-cell lymphoma: A retrospective study in China
Yan-ping Chen et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2017)
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study
Yael P. Mosse et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC
V. Selvarajan et al.
LEUKEMIA (2017)
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
Heikki Kuusanmaki et al.
ONCOTARGET (2017)
Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
Chen Chen et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease
S. H. Lim et al.
ANNALS OF ONCOLOGY (2017)
Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report
Jianping Lai et al.
BMC CANCER (2017)
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy
Toshihiro Nagato et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type
Sung Hoon Sim et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase
Yok-Lam Kwong et al.
BLOOD (2017)
Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin
S. J. Kim et al.
ANNALS OF ONCOLOGY (2016)
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL)
D. Tan et al.
ANNALS OF ONCOLOGY (2016)
EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma
Junli Yan et al.
BLOOD (2016)
Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type
Akito Dobashi et al.
GENES CHROMOSOMES & CANCER (2016)
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
Xi-wen Bi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study
Zheng Li et al.
LANCET ONCOLOGY (2016)
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
Seok Jin Kim et al.
LANCET ONCOLOGY (2016)
Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior
Mineui Hong et al.
MODERN PATHOLOGY (2016)
Expression and significance of Ku80 and PDGFR-α in nasal NK/T-cell lymphoma
Jun Li et al.
PATHOLOGY RESEARCH AND PRACTICE (2016)
Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation
Troy A. McEachron et al.
PEDIATRIC BLOOD & CANCER (2016)
Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis
Wook Youn Kim et al.
VIRCHOWS ARCHIV (2016)
MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma
Xudong Zhang et al.
ONCOTARGET (2016)
Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases
Bradley M. Haverkos et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
A Phase II Study of Bortezomib-GIFOX (Gemcitabine, Ifosfamide, Oxaliplatin) in Patients with Newly Diagnosed Natural-Killer/T-Cell Lymphoma
Tiffany Tang et al.
BLOOD (2016)
CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type
Liang Wang et al.
ANNALS OF HEMATOLOGY (2015)
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Y. Shi et al.
ANNALS OF ONCOLOGY (2015)
Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma
Yun-Wen Chen et al.
BLOOD (2015)
CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma
Takumi Kumai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Global Promoter Methylation Analysis Reveals Novel Candidate Tumor Suppressor Genes in Natural Killer Cell Lymphoma
Can Kuecuek et al.
CLINICAL CANCER RESEARCH (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs
Seok-Goo Cho et al.
MOLECULAR THERAPY (2015)
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
Lu Jiang et al.
NATURE GENETICS (2015)
LMP1 promotes nasal NK/T-cell lymphoma cell function by eIF4E via NF-κB pathway
Lu Sun et al.
ONCOLOGY REPORTS (2015)
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
Can Kucuk et al.
NATURE COMMUNICATIONS (2015)
Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type
Seungbok Lee et al.
ONCOTARGET (2015)
Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial
Daryl Tan et al.
LANCET HAEMATOLOGY (2015)
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma
Takumi Kumai et al.
ONCOIMMUNOLOGY (2015)
Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator
Seok Jin Kim et al.
HAEMATOLOGICA (2015)
Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma
Penny Anders et al.
LEUKEMIA & LYMPHOMA (2015)
Differences in incidence and trends of haematological malignancies in Japan and the United States
Dai Chihara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma
A. Bouchekioua et al.
LEUKEMIA (2014)
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)
Kristen Ganjoo et al.
LEUKEMIA & LYMPHOMA (2014)
HACE1 Is a Tumor Suppressor Gene Candidate in Natural Killer Cell Neoplasms
Can Kuecuek et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
International analysis of the frequency and outcomes of NK/T-cell lymphomas
Basem M. William et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2013)
Epstein-Barr virus-associated natural killer/T-cell lymphomas
Naoko Asano et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2013)
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
Junli Yan et al.
BLOOD (2013)
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
Yok-Lam Kwong et al.
BLOOD (2012)
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial
Seok Jin Kim et al.
EUROPEAN JOURNAL OF CANCER (2012)
Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses
Kennosuke Karube et al.
BLOOD (2011)
Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling
Siok-Bian Ng et al.
JOURNAL OF PATHOLOGY (2011)
PRDM1 is a tumor suppressor gene in natural killer cell malignancies
Can Kuecuek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type
Yenlin Huang et al.
BLOOD (2010)
Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma
Hong-Qiang Guo et al.
DISEASE MARKERS (2010)
Frequent concomitant epigenetic silencing of the stress-responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma
Li Fu et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type
Biyun Wang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas
Jianming Ying et al.
EPIGENETICS (2007)
Concomitant increase of LMP1 and CD25 (IL-2-receptor α) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3
Miki Takahara et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors
ATC Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
